IDEAYA Biosciences, Inc. IDYA
Set alert
At close
Pre-market · Nov 2, 8:23 AM ET
- YTD
- -7.55%
- 1 year
- +1.14%
- Open
- 32.76
- Prev close
- 32.89
- Mkt cap
- 3.08B
- Vol
- 838.03K
- Avg vol
- 818.03K
- EPS
- -1.94
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.70
- High
- 33.50
- Forward P/E
- -7.76
- Beta
- -0.04
- Short ratio
- 9.87
- Inst. own
- 107.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 37.39
- 200-d avg
- 34.04
- 1y target
- 52.38
5D chart
Signals (121)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 29, 3:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:30 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:55 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:20 AM | 6 days ago |
| RSI: Oversold | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 6 days ago |
News
3 days ago prnewswire.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization…
5 days ago zacks.com
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 days ago defenseworld.net
IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell?
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $34.19 and traded…
-
2 weeks ago benzinga.com
IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and…
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating
William Blair analyst Alethia Young initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57
Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.
-
1 month ago benzinga.com
IDEAYA Biosciences Announced First Patient Has Been Dosed In The OptimUM-11 Phase 3 Registrational Trial Evaluating Darovasertib In Combination With Crizotinib For Patients With Primary Uveal Melanoma
Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for…
-
2 months ago benzinga.com
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target
Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and maintains $42 price target.
-
2 months ago benzinga.com
IDEAYA Sets November R&D Day To Share New Pancreatic Cancer Research And Strategy
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in…
-
2 months ago benzinga.com
IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to…
-
2 months ago benzinga.com
IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma
Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS…
-
2 months ago benzinga.com
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59
Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60
Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
-
3 months ago benzinga.com
IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses…
-
3 months ago benzinga.com
Ideaya Biosciences Initiated Part 2 Monotherapy Expansion In Its Phase 1/2 Trial Of IDE892 In Mtap-Deleted Solid Tumors, With A Focus On Non-small Cell Lung Cancer And Pancreatic Ductal Adenocarcinoma
IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no…
-
3 months ago benzinga.com
IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical Pipeline
IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. Presenting Author - Mark Shackleton, MBBS, PhD,…
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63
Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $65 to $63.
-
4 months ago benzinga.com
Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Pancreatic And Lung Cancers
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like propertiesIDE892 has a CYP3A4 IC50 greater than 45…
-
4 months ago benzinga.com
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target
Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.
4 months ago benzinga.com
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak earnings. Other stocks also down in pre-market.
4 months ago benzinga.com
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
4 months ago benzinga.com
IDEAYA Biosciences Plans To Commence $300M Common Stock Offering
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain…
-
5 months ago benzinga.com
IDEAYA Enters Collaboration With Roche To Evaluate The Efficacy And Safety Of IDE892, Its Investigational PRMT5 Inhibitor, With Roche's RG6505
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1…
-
5 months ago benzinga.com
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target
Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.
-
5 months ago benzinga.com
IDEAYA Biosciences And Servier Presented Complete Data From Primary Analysis Of Phase 2/3 OptimUM-02 Trial For Negative Metastatic Uveal Melanoma At ASCO Annual Meeting
Key Findings from OptimUM-02Primary endpoint (Phase 2 portion): progression free survival by BICRThe trial met the primary endpoint, with patients treated with the darovasertib combination…
-
5 months ago benzinga.com
Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $50
Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $52 to $50.
-
6 months ago benzinga.com
IDEAYA Biosciences Q1 EPS $(1.11) Misses $(0.98) Estimate, Sales $6.560M Beat $5.008M Estimate
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.98) by 13.27 percent. This is a 35.37 percent decrease over losses…
-
6 months ago benzinga.com
IDEAYA Biosciences Reveals Late-Breaking Abstract Oral Presentation At ASCO 2026 To Provide Complete Data from Phase 2/3 Registrational Trial Of Darovasertib In Combination With Crizotinib In 1L HLA*A2-Negative Metastatic Uveal Melanoma
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the…
-
6 months ago benzinga.com
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $35
Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral and raises the price target from $31 to $35.
-
6 months ago benzinga.com
Wells Fargo Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $48
Wells Fargo analyst Eva Fortea Verdejo maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from $44 to $48.
-
6 months ago benzinga.com
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $53
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $49 to $53.
-
6 months ago benzinga.com
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $58
Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $52 to $58.
-
6 months ago benzinga.com
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $54
Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $50 to $54.
6 months ago benzinga.com
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
6 months ago benzinga.com
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars
IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.
-
6 months ago benzinga.com
Market-Moving News for April 13th
IMA: 41% | ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Disease Treatments IDYA: 37% | IDEAYA Biosciences and Servier's Topline Data From Phase 2/3 OptimUM-02…
-
6 months ago benzinga.com
IDEAYA Biosciences and Servier's Topline Data From Phase 2/3 OptimUM-02 Trial Of Darovasertib Plus Crizotinib In HLA-A*02:01-Negative Metastatic Uveal Melanoma Met Primary Endpoint
Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30,…
6 months ago benzinga.com
Stock Market Today: Dow Futures Fall As Trump Announces Strait Of Hormuz Blockade—Goldman Sachs, Fastenal In Focus (UPDATED)
Editor’s note: The future prices of benchmark tracking ETFs and pre-market prices of stocks have been updated. U.S. stock futures declined on Monday following Friday's mixed close. Futures of major…
6 months ago benzinga.com
Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline results from ongoing Phase 2/3 trial.
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
6 months ago benzinga.com
IDEAYA And Servier To Release Topline Results From Phase 2/3 OptimUM-02 Trial In Metastatic Uveal Melanoma On April 13, 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and…
-
7 months ago benzinga.com
IDEAYA Biosciences Enrolls First Patient In Phase 1 Dose Escalation Trial Of IDE574 For Multiple Solid Tumors
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and…
-
7 months ago benzinga.com
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target
Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $52 price target.
-
7 months ago benzinga.com
Cancer Drug Maker IDEAYA Biosciences Starts First Patient Trial For New Combo Therapy, Tests New Drug Pair Aimed At Hard-To-Treat Cancers
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced first-patient-in for a Phase 1 clinical…
-
7 months ago benzinga.com
Ideaya Biosciences Enrolls The First Patient In Its Phase 1 Trial Of IDE892 for MTAP-Deleted Solid Tumors, Including Non-small Cell Lung Cancer And Pancreatic Cancer
Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in MTAP-deleted cell linesIDE892 is being…
-
8 months ago benzinga.com
Reported Friday, Biocytogen Announces First Patient Dosed In IDEAYA's Phase 1 Trial Of First-In-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034, Triggering $5M Milestone Payment
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA's PARG…
-
8 months ago benzinga.com
IDEAYA Biosciences Enrolls First Patient In Phase 1 Trial Of IDE034, A Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC For Solid Tumors
Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161B7H3/PTK7 co-expressed in 30-40%…